Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer

Published:2013-09 Issue:9 Volume:8 Page:1148-1155
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lee Victor H.F.,Tin Vicky P.C.,Choy Tim-shing,Lam Ka-on,Choi Cheuk-wai,Chung Lap-ping,Tsang Janice W.H.,Ho Patty P.Y.,Leung Dennis K.C.,Ma Edmond S.K.,Liu Jing,Shek Tony W.H.,Kwong Dora L.W.,Leung To-wai,Wong Maria P.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N Engl J Med,2009

2. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan;Huang;Clin Cancer Res,2004

3. Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?;Gazdar;Trends Mol Med,2004

4. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors;Gazdar;Oncogene,2009

5. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants;JTO Clinical and Research Reports;2024-02

2. Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study;BMC Cancer;2024-01-12

3. Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients;Journal of Cancer Research and Practice;2024-01

4. Effects of Next-Generation Sequencing on Lung Cancer Survivorship in Rural versus Urban Populations;International Journal of Cancer Care and Delivery;2023-12-15

5. The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors;Translational Lung Cancer Research;2023-09